scholarly journals Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder

2001 ◽  
Vol 179 (6) ◽  
pp. 514-518 ◽  
Author(s):  
D. Michelson ◽  
C. Allgulander ◽  
K. Dantendorfer ◽  
A. Knezevic ◽  
D. Maierhofer ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Dose Escalation ◽  
Serotonin Reuptake ◽  
Serotonin Reuptake Inhibitors ◽  
Panic Attacks ◽  
Satisfactory Response ◽  
End Point ◽  
Antidepressant Efficacy ◽  
Dosing Regimens

BackgroundAlthough serotonin reuptake inhibitors are effective in panic disorder, questions concerning whether doses associated with antidepressant efficacy are also effective for panic disorder remain.AimsTo assess the efficacy of the usual antidepressant dose of fluoxetine in treating full panic attacks.MethodPatients with panic disorder were randomised to placebo or to fluoxetine initiated at 10 mg daily for I week and then increased to 20 mg daily. The trial lasted 12 weeks, but after 6 weeks patients who had failed to achieve a satisfactory response were eligible for dose escalation to a maximum of 60 mg of fluoxetine daily.ResultsFluoxetine was associated with a statistically significantly greater proportion of panic-free patients compared with placebo after 6 weeks and at end-point.ConclusionsFluoxetine at a dose of 20 mg daily is safe and efficacious in reducing symptoms of panic disorder. Patients who fail to obtain a satisfactory response at 20 mg daily may benefit from further dose increases.

Panic Disorder, Treatment With Selective Serotonin Reuptake Inhibitors, and Cholesterol Levels

2006 ◽  
Vol 26 (5) ◽  
pp. 538-540 ◽  
Author(s):  
Andr??s Herr??n ◽  
Maria L. Ram??rez ◽  
Maria Carrera ◽  
Maria T. Garc??a-Unzueta ◽  
Deirdre Sierra-Biddle ◽  
...  
Keyword(s):  
Panic Disorder ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Cholesterol Levels ◽  
Disorder Treatment

scholarly journals Panic Disorder and Serotonin Reuptake Inhibitors Predict Coupling of Cortical and Cardiac Activity

2013 ◽  
Vol 39 (2) ◽  
pp. 507-514 ◽  
Author(s):  
Erik M Mueller ◽  
Christian Panitz ◽  
Yvonne Nestoriuc ◽  
Gerhard Stemmler ◽  
Jan Wacker
Keyword(s):  
Panic Disorder ◽  
Serotonin Reuptake ◽  
Cardiac Activity ◽  
Serotonin Reuptake Inhibitors

Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment

2019 ◽  
Vol 33 (11) ◽  
pp. 1340-1351 ◽  
Author(s):  
Laiana A Quagliato ◽  
Fiammetta Cosci ◽  
Richard I Shader ◽  
Edward K Silberman ◽  
Vladan Starcevic ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Risk Factor ◽  
Panic Disorder ◽  
Adverse Effects ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Meta Analysis ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Short Term

Background:Benzodiazepines (BZs) and selective serotonin reuptake inhibitors (SSRIs) are effective in the pharmacologic treatment of panic disorder (PD). However, treatment guidelines favor SSRIs over BZs based on the belief that BZs are associated with more adverse effects than SSRIs. This belief, however, is currently supported only by opinion and anecdotes.Aim:The aim of this review and meta-analysis was to determine if there truly is evidence that BZs cause more adverse effects than SSRIs in acute PD treatment.Methods:We systematically searched Web of Science, PubMed, Cochrane Central Register of Controlled Trials, and clinical trials register databases. Short randomized clinical trials of a minimum of four weeks and a maximum of 12 weeks that studied SSRIs or BZs compared to placebo in acute PD treatment were included in a meta-analysis. The primary outcome was all-cause adverse event rate in participants who received SSRIs, BZs, or placebo.Results:Overall, the meta-analysis showed that SSRIs cause more adverse events than BZs in short-term PD treatment. Specifically, SSRI treatment was a risk factor for diaphoresis, fatigue, nausea, diarrhea, and insomnia, whereas BZ treatment was a risk factor for memory problems, constipation, and dry mouth. Both classes of drugs were associated with somnolence. SSRIs were associated with abnormal ejaculation, while BZs were associated with libido reduction. BZs were protective against tachycardia, diaphoresis, fatigue, and insomnia.Conclusion:Randomized, blinded studies comparing SSRIs and BZs for the short-term treatment of PD should be performed. Clinical guidelines based on incontrovertible evidence are needed.

The effect of Citalopram in panic disorder

1997 ◽  
Vol 170 (6) ◽  
pp. 549-553 ◽  
Author(s):  
A. G. Wade ◽  
U. Lepola ◽  
H. J. Koponen ◽  
V. Pedersen ◽  
T. Pedersen
Keyword(s):  
Panic Disorder ◽  
Serotonin Reuptake ◽  
Tricyclic Antidepressants ◽  
Rating Scales ◽  
Panic Attacks ◽  
Tolerability Profile ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Parallel Group ◽  
Number Of Patients

BackgroundCitalopram is a serotonin reuptake inhibitor which has been demonstrated to be highly selective and with a superior tolerability profile to the classical tricyclic antidepressants. This study was designed to test whether there was any difference in eff icacy in the management of panic disorder (PD) between Citalopram and placebo.MethodThis was a double-blind, placebo and clomipramine controlled, parallel group eight-week study. A total of 475 patients with PD, with or without agoraphobia, were randomised to treatment with either placebo, clomipramine 60 or 90 mg/day, or Citalopram 10 or 15 mg/day, 20 or 30 mg/day, or 40 or 60 mg/day. Doses were increased over the first three weeks, stabilised during the fourth week and fixed between weeks five and eight.ResultsTreatment with Citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment. All rating scales examined suggested that Citalopram 20 or 30 mg was more effective than Citalopram 40 or 60 mg.ConclusionThe most advantageous benefit/risk ratio for the treatment of PD was associated with citalopram 20 or 30 mg/day.

Sign in / Sign up

Export Citation Format

Share Document